Point-of-Care Diagnostics

The market for rapid testing is expanding with compelling new technologies and the outlook is very bright. This year’s Point-of-Care Diagnostics conference will cover wearables, cell-based devices, point-of-care assays for antibiotic resistance and integrated diagnostic and treatment devices. This is the meeting place for diagnostic developers and end-users to talk about the future of mobile testing and how it is leading the transformation in medicine.

Scientific Advisory Board

Gyorgy Abel, M.D., Ph.D., Director, Molecular Diagnostics, Immunology & Clinical Chemistry, Laboratory Medicine, Lahey Hospital & Medical Center, United States

Holger Becker, Ph.D., Founder & CSO, microfluidic ChipShop GmbH, Germany


12:00 – 13:00 Registration


13:00 Chairperson’s Opening Remarks

Gyorgy Abel, M.D., Ph.D., Director, Molecular Diagnostics, Immunology & Clinical Chemistry, Laboratory Medicine, Lahey Hospital & Medical Center, United States


Wilfried von EiffWilfried von Eiff, Ph.D., Academic Director, Center for Health Care Management and Regulation, HHL, Leipzig Graduate School of Management, Germany

POCT technology enables us to leverage medical quality, patient outcome and economy of clinical processes. In two randomized single center trials the advantages of a POCT setting compared to a central lab test environment could be demonstrated. In an emergency department, POCT contributes to avoiding crowding effects and to reducing length-of-stay of patients suffering from non-specific thoracic pain. Furthermore, cost saving and efficiency effects were achieved using POCT for glucose monitoring onwards.

13:35 The Added Value POC Platforms for Pathogen Detection in Diagnostic Microbiology

Eric_ClaasEric C.J. Claas, Ph.D., Associate Professor, Molecular Medical Microbiologist, Medical Microbiology, Leiden University Medical Center, The Netherlands

Over the last few decades nucleic acid amplification methods have revolutionized diagnostic microbiology. Initially, advanced laboratory skills were required for reliable implementation of these techniques but in recent years automated systems have become available for advanced processing of clinical samples. Different formats are available to accommodate specific laboratory requirements varying in the number of samples that can be processed, the number of pathogens that can be simultaneously detected, and time to result. An overview of the possibilities will be presented with a view on future diagnostic microbiology.

14:05 Point-of-Care Testing: A European Perspective

Anders_LarssonAnders Larsson, Ph.D., Professor, Medical Sciences, Uppsala University, Sweden

Over the past decades the availability and use of point-of-care testing (POCT) have steadily increased in Europe. Properly utilized, POCT has been shown to yield measurable improvements in patient care, workflow, and significant financial benefits in a number of different settings. It is important however that POCT is effectively integrated in the patient care including quality assurance systems and electronic handling of results.

14:35 Refreshment Break in the Exhibit Hall with Poster Viewing


15:10 Chairperson’s Remarks

Holger Becker, Ph.D., Founder & CSO, microfluidic ChipShop GmbH, Germany

15:15 Implementation of POCT Quality Standards to Optimize the Clinical Process Reliability


Peter_LuppaPeter B. Luppa, Ph.D., Head, Central Laboratory, Institute for Clinical Chemistry, Technische Universität München, Germany

A POCT coordinator in a hospital has a pivotal role for quality assurance. He oversees all POCT processes and ensures that all necessary regulatory issues are met, establishing both quality and competence of testing. Implementation of POCT into clinical practice means: Assessing analytical reliability, evaluating clinical significance and establishing a comprehensive quality management system. Only when analytical performance characteristics and clinical limits are known, the POCT process reliability can be optimised.

15:45 A Universal POC Platform for Molecular, Immunological and Clinical Diagnostics

Holger_BeckerHolger Becker, Ph.D., Founder & CSO, microfluidic ChipShop GmbH, Germany

We have developed a universal diagnostic system which, as a platform, can handle molecular, immunological and clinical chemistry tests on a single instrument platform in a low resource setting. One example for a molecular diagnostic test on this platform is the fully automated sample-in answer-out cartridge for a rapid detection of mycobacterium tuberculosis (TB). This platform will be used in the future as an open platform to allow users a fast-track to bring their own assays onto a microfluidic cartridge format.

16:15 Emerging Technologies in Point-of-Care Diagnostics for Resource-Limited Settings

Ranald Sutherland, Ph.D., Head, Business Development, FIND Foundation for Innovative New Diagnostics

Diagnosing infectious diseases at the point at which care is delivered has the potential to save many lives, especially where access to laboratories is poor. Whether caring for an individual patient or responding to a worldwide pandemic, establishment of a microbial cause is fundamental to quality care. Emerging technologies enable this with new speed, sensitivity, and simplicity of use. However, there are significant challenges to the development and clinical integration of the new generation of diagnostic tests.

16:45 Close of Day One




8:30 Registration and Morning Coffee

9:00 Chairperson’s Remarks

Till T. Bachmann, Ph.D., Reader, Personalised Medicine in Infectious Disease; Deputy Head, Division of Infection and Pathway Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, United Kingdom

9:05 A Handheld qPCR Device for Use in the Field

Jo_StantonJo-Ann Lee Stanton, Ph.D., Senior Research Fellow, Anatomy, University of Otago, New Zealand

Diagnosis of infectious disease at the initial point-of-care permits rapid infection containment, accurate diagnosis and the immediate implementation of appropriate treatment. qPCR is rapid, sensitive and accurate. We have invented a battery-powered, hand held qPCR device that can be used for point-of-care diagnostics. This talk will explore use of our handheld quantitative PCR device in non-laboratory environments.

9:35 Amplification Free Electrochemical Detection of Nucleic Acids for Rapid Antimicrobial Resistance Testing at Point-of-Care

Till_BachmannTill T. Bachmann, Ph.D., Reader, Personalised Medicine in Infectious Disease; Deputy Head, Division of Infection and Pathway Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, United Kingdom

Rapid diagnostics is of utmost importance to quickly initiate the correct antibiotic therapy and avoid the use of inappropriate antibiotics. Direct, amplification free detection of nucleic acids offers the possibility to shorten the time to result and specific sample preparation requirements need to be considered when setting up such assays. We have demonstrated the direct detection of nucleic acid antimicrobial resistance biomarkers from genomic and plasmid DNA from MRSA and CPE respectively. We used electrochemical impedance spectroscopy and disposable electrodes and will discuss their integration in sample to answer tests.

10:05 Point-of-Impact Testing in the Emergency Department: Rapid Diagnostics for Respiratory Viral Infections
Randy Poelman, Ph.D. Candidate, Medical Microbiology, University Medical Center Groningen, The Netherlands

10:35 Coffee Break in the Exhibit Hall with Poster Viewing

11:15 LAMP: Fast and Simple Point-of-Care Molecular Diagnostics of Bacteria and Viruses
Polona Kogovsek, Ph.D., Researcher, Biotechnology & Systems Biology, National Institute of Biology, Slovenia

11:45 A Rapid, Amplification-Free, and Sensitive Diagnostic Assay for Single-Step Multiplexed Fluorescence Detection of MicroRNA

Xue_QiuXue Qiu, Institut d’Electronique Fondamentale, Université Paris-Sud, France

I will present a fully homogeneous multiplexed microRNA FRET assay that combines careful biophotonic design with various RNA hybridization and ligation steps. The single-step and amplification-free assay provides a unique combination of performance parameters compared to state-of-the-art miRNA detection technologies. Precise quantification of miRNA-20a, -20b, and -21 with detection limits between 0.2 and 0.9 nM in 7.5 mL serum samples demonstrate the feasibility of both high throughput and point-of-care clinical diagnostics.

12:15 Enjoy Lunch on Your Own

14:15 Dessert Break in the Exhibit Hall with Poster Viewing


14:55 Chairperson’s Remarks

Holger Becker, Ph.D., Founder & CSO, microfluidic ChipShop GmbH, Germany

15:00 Lab-on-DVD: Advanced Cellular and Molecular Diagnostics at Resource Limited Settings

Aman_RussomAman Russom, Ph.D., Associate Professor and Head, Clinical Microfluidics Lab, Division of Proteomics and Nanobiotechnology, Science for Life Laboratory, KTH Royal Institute of Technology, Sweden

Microfluidics and the concept of lab-on-a-chip continue to gain traction as a successful emerging field that aims to integrate complex biochemical analyses into automated systems. One of the most promising applications for these microfluidic systems is in point-of-care biological analysis. Here, I will describe and discuss a low-cost “Lab-on-DVD” platform capable of integrating sample handling and detection for POC blood diagnostics.

15:30 Global Health Diagnostics Demands

Francis_MoussyFrancis Moussy, Ph.D., Lead, AMPR Diagnostics Innovation, Essential Medicines and Health Products Department, World Health Organization (WHO), Switzerland

Low-cost and robust POC diagnostics that are suitable for remote health care centers in low- and middle-income countries are needed to facilitate surveillance and identification of etiological agents (and/or biological responses) and thus guide decisions for timely and appropriate treatment and reporting in places where almost no tools are available. One approach towards such diagnostic tools is to facilitate the development of multipurpose POC diagnostic devices.

16:00 The Digital Revolution on a Disc for Next-Generation Point-of-Care Diagnostics

Jens_DucreeJens Ducrée, Ph.D., Biomedical Diagnostics Institute, National Centre of Sensor Research, School of Physical Sciences, Dublin City University, Ireland

This talk will review significant advances on comprehensive process integration, automation and parallelization of bioanalytical assays on a compact and widely autonomous microfluidic platform. Similar to modern microelectronics, this next-generation Lab-on-a-Disc platform allows complex logical flow control architectures generated by strategic repetition of elementary building blocks such as transistors. Several applications in point-of-care diagnostics such as immunoassay, general chemistry, nucleic acid testing and cell counting will be demonstrated.

16:30 Next-Generation Diagnosis of Bacteremia in Septic Patients
Kai Sohn, Ph.D., Deputy Department Head, Functional Genomics, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Germany

17:00 Refreshment Break

17:15 Centrifugal Microfluidic Platform (LabDisk) as a Multi-Purpose, Multi-Target Diagnostic Tool for Patient Management at the Point-of-Care

Konstantinos_MitsakakisKonstantinos Mitsakakis, Ph.D., Project Manager & International Business Development, Hahn-Schickard & IMTEK-University of Freiburg, Germany

The LabDisk is a CD-shaped microfluidic platform with all reagents integrated for on-site sample-to-answer diagnosis of single or multiple infectious diseases stemming from parasites, bacteria, viruses, or co-infections of theirs. By combining molecular diagnostics and protein biomarker detection, the LabDisk offers increased reliability in pathogen species identification. An overview of case-studies in infectious disease diagnostics will be presented, namely on neonatal sepsis, respiratory tract infections, antibiotic resistance, febrile tropical infections.

17:45 Integrated Sample-Prep and Immunoassay Array Platform for High-Sensitivity, Low-Complexity Multiplexed POC Diagnostics

John_CarranoJohn C. Carrano, Ph.D., President & CEO, Paratus Diagnostics LLC, United States

Detection of infectious pathogens is critical to proper patient care and management of outbreaks, yet many existing diagnostic tests fail to provide adequate sensitivity and simplicity for use in an out-patient setting. Our solution resolves the problems associated with long delays in test results processed at a central laboratory thereby informing clinical decision-making during the normal course of the patient visit to the clinic. In this talk we will present a solution for a high-sensitivity, low-complexity multiplexed POC diagnostic test that addresses and resolves each of these challenges through the application or our unique and differentiated technologies.

18:15 Close of Conference